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ABSTRACT.
Chronic Lymphocytic Leukemia (CLL) cells develop chemo-resistance over time. Most anti-cancer agents function through induction of apoptosis, and resistance against these agents is likely to be caused by selection during the treatments of CLL-cells with defects in the particular apoptosis pathway that is triggered by these compounds. Anti-cancer agents that function through alternative apoptotic pathways therefore might be useful in treating chemo-resistant CLL. Triterpenoids represent a class of naturally occurring and synthetic compounds with demonstrated anti-tumor activity. We examined the effects of Consequently, resistance to apoptosis has been established as one of the mechanisms responsible for the failure of therapeutic approaches in many types of cancers, including hematopoietic malignancies. B-cell chronic lymphocytic leukemia (CLL) is the most common form of leukemia in adults in the Western Hemisphere, with over 12,000 new cases diagnosed annually in the United States alone 1 . CLL is considered an incurable disease. Therefore, identifying new agents with novel mechanisms of action that complement conventional cytotoxic therapies and that abrogate chemo-resistance will be necessary, if further advances in the therapy of this disease are to be realized.
Apoptosis is caused by the activation in cells of a family of cysteine proteases known as Caspases 2 . At least two major pathways for Caspase activation have been delineated, including a pathway linked to Tumor Necrosis Factor (TNF) family of death receptors ("extrinsic") and a pathway activated by mitochondria ("intrinsic") 3,4 . The mechanisms by which anti-neoplastic drugs kill leukemia cells may be diverse, but most cytotoxic agents seem to employ the intrinsic pathway for inducing apoptosis 5 .
Consequently, when resistance develops, defects in the mitochondria-initiated pathway for cell death are often found. With the extrinsic pathway, ligand binding induces clustering of TNF-family death receptors, causing in recruitment of Caspase-binding adaptor proteins to their cytosolic domains, and resulting in Caspase activation by the "induced proximity" mechanism 6 . The intrinsic pathway is triggered by Cytochrome c release from mitochondria, which binds the Caspase-activating protein Apaf-1, forming only.
For personal use at PENN STATE UNIVERSITY on February 21, 2013. bloodjournal.hematologylibrary.org From 4 the apoptosome. The apical proteases in the extrinsic and intrinsic pathways are Caspases-8 and -9, respectively. Activation of both extrinsic and intrinsic pathways results in the activation of downstream Caspases such as Caspase-3, 6, and 7 7 .
CLL B-cells are generally known to be resistant to apoptosis induced by TNFfamily death ligands, such as TNF-, FasL, and TRAIL 8-11 and unpublished data. It is possible, however, that the extrinsic apoptosis pathway is blocked at a proximal, surface level in CLL B-cells, and that downstream portions of the pathway remain functional.
Therefore it is important to identify anti-cancer agents which operate through the "alternative" extrinsic apoptosis pathway in CLL B-cells, especially for patients who develop resistance to conventional chemotherapeutic agents.
Triterpenoids represent a class of naturally occurring and synthetic PPAR ligands with demonstrated anti-tumor activity. The oleanane triterpenoid 2-Cyano-3,12-dioxoolean-1,9-dien-28-oic acid (CDDO) and related synthetic triterpenoids have pleiotrophic actions, including modulation of PPAR transcriptional activity and suppression of NF-B activation [12] [13] [14] [15] . CDDO has been demonstrated to activate Caspase-8 in cultured leukemia cell lines and osteosarcoma cells 13, 16, 17 . We therefore explored the effects of CDDO on apoptosis of cultured CLL B-cells freshly isolated from patients. We show here that CDDO is a potent apoptosis-inducing agent in CLL B-cells in vitro, and provide evidence that CDDO function through the extrinsic apoptosis pathway. CDDO appears to be effective even in chemo-refractory CLL specimens that have defects in the intrinsic apoptosis pathway. 
specimen differed in terms of optimal electroporation conditions, electroporation parameters were first optimized for each sample before proceeding to Caspase activity assays. It is interesting to note that only a small percentage of the CLL cells that were successfully transduced with protein (gate R1 in Figure 3A) were positive for 7-AAD staining 1 hour after electroporation, although this percentage varied among CLL samples. This result further indicates that the majority of CLL-cells remain viable after electroporation. As shown in Figure 3B 
CDDO activates the extrinsic apoptosis pathway in CLL.
To determine if CDDO induces apoptosis in CLL through activation of the extrinsic pathway, we cultured CLL B-cells with CDDO after introducing the Caspase-8
inhibitor CrmA or the Caspase-9 inhibitor XIAP-BIR3 by electroporation. For 
CDDO down-regulates the anti -apoptotic protein FLIP in CLL cells.
We examined the effects of CDDO and various PPAR modulators on the expression in CLL B-cells of apoptosis regulatory proteins known to operate within the extrinsic pathway, including DR4, DR5, FADD, DAP3, and FLIP. CDDO potently reduced levels of the anti-apoptotic FLIP protein in all CLL B-cell samples analyzed (n=15), while having no affect on the levels of other proteins involved in the extrinsic only.
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Troglitazone had no effect on levels of FLIP or other extrinsic proteins tested (Fig. 7A) . Dose-response experiments showed a correlation between CDDO concentration, downregulation of FLIP protein levels, and extent of apoptosis induction in cultured CLL Bcells ( Figure 7B ).
FLIP reductions are inadequate to explain pro-apoptotic effect of CDDO.
To determine whether down-regulation of FLIP is sufficient to account for the 
CDDO sensitizes some CLL B-cells to TRAIL-induced apoptosis.
The modulation of FLIP in CLL B-cells by CDDO raised the question of whether CDDO could be used to sensitize CLL B-cells to TNF-family death receptor agents such as TRAIL. To explore this idea, we cultured CLL B-cells in the presence or absence of 1 µM CDDO for 6 hours (which was determined to be adequate for reducing FLIP protein We found that while CDDO induced apoptosis of CLL B-cells, the thiazoladinedione troglitazone did not and the CDDO analogue, CDDO-Me, was less potent than CDDO. In this regard, troglitazone is a more potent PPAR agonist than CDDO, which has only weak agonist activity 12 . Furthermore, CDDO-Me is a PPAR antagonist 44 .
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